Study

EORTC-2333-GUCG

Discrete Choice Experiment to understand patient preferences and their assessment of benefits and risks of intermittent versus continuous Androgen Deprivation Therapy in the era of AR pathway inhibitors.

Study documentation Back to result

Trial Status

Recruiting

Dates

Date of activation: 09-Oct-2024

Data management at EORTC

Design

QoL Non Module Study Development

Study Staff

  • Ahu Alanya (Clinical Scientist), EORTC Headquarters, Brussels
  • Corneel Coens (Statistician), EORTC Headquarters, Brussels